Latest data from January 14, 2022
Number of Health Center respondents = 33 (85% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 12,540 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 43.63% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 4,728 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 48.49% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 50.10% | 45.47% |
| White, Hispanic/Latino Patients | 5.95% | 7.47% |
| Black/African American, Non-Hispanic/Latino Patients | 22.60% | 24.56% |
| Black/African American, Hispanic/Latino Patients | 0.65% | 0.78% |
| Asian Patients3 | 1.27% | 1.21% |
| American Indian/Alaska Native Patients3 | 0.42% | 0.42% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.27% | 0.19% |
| Patients with More Than One Race3 | 2.61% | 2.58% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 5.01% | 5.60% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.34% | 1.92% |
| Unreported/Refused to Report Race and Ethnicity | 8.77% | 9.79% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 2,895 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 63.00% |
| COVID-19 Immunization Series Completed | 2,088 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 66.02% |
| COVID-19 Immunization Series Additional | 4,831 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 51.88% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 32.30% | 29.55% | 43.12% |
| White, Hispanic/Latino Patients | 14.20% | 14.56% | 7.49% |
| Black/African American, Non-Hispanic/Latino Patients | 18.03% | 17.91% | 16.54% |
| Black/African American, Hispanic/Latino Patients | 1.42% | 2.11% | 0.41% |
| Asian Patients3 | 1.45% | 0.81% | 1.55% |
| American Indian/Alaska Native Patients3 | 0.69% | 0.34% | 4.10% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.24% | 0.14% | 0.19% |
| Patients with More Than One Race3 | 3.32% | 4.26% | 1.53% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 15.65% | 17.29% | 14.68% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 1.83% | 2.30% | 1.80% |
| Unreported/Refused to Report Race and Ethnicity | 10.88% | 10.73% | 8.59% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 12.12% |
| 1 to 24 Hours | 15.15% |
| More Than 24 Hours | 72.73% |
| N/A | 0.00% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 0.00% |
| Staffing to administer the vaccine | 63.64% |
| Vaccine confidence | 36.36% |
| Vaccine storage capacity | 0.00% |
| Vaccine supply | 9.09% |
| Other | 9.09% |
| None | 15.15% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 18.18% |
| Average Percent of Health Center Visits Conducted Virtually | 20.91% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 57.58% |
| Number of Mobile Van Sites | 16 |
| Number of Pop-up Clinics | 27 |
| Number of School-Based Vaccination Sites | 5 |
| Number of Family Vaccination Clinics | 81 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 9.09% |
| Refer patients to another organization that provides monoclonal antibody therapies | 66.67% |
| None | 27.27% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 12.12% |
| Patient awareness/education | 3.03% |
| Staffing capacity | 12.12% |
| Therapy administration/onsite logistics | 9.09% |
| Other | 0.00% |
| None | 72.73% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 16 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 20,208 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provide to Existing Health Center Patients | 75.00% |
| Provide to General Public Who Came to the Health Center | 75.00% |
| Provide at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 37.50% |
| Provide at Other Community Events | 37.50% |
| Provide through direct outreach to specific populations (i.e., individuals experiencing homelessness, MSAWs, residents of public housing, individuals with limited English proficiency) | 12.50% |
| Other | 37.50% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 4 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication5 | 23.08% |
Oral Antiviral Medication Distribution by Race and Ethnicity5
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | 61.54% |
| White, Hispanic/Latino Patients | 15.38% |
| Black/African American, Non-Hispanic/Latino Patients | 0.00% |
| Black/African American, Hispanic/Latino Patients | 0.00% |
| Asian Patients3 | 0.00% |
| American Indian/Alaska Native Patients3 | 0.00% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.00% |
| Patients with More Than One Race3 | 0.00% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 7.69% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.00% |
| Unreported/Refused to Report Race and Ethnicity | 0.00% |
Oral Antiviral Medication Distribution by Special/Vulnerable Population5
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | 0.00% |
| Patients Experiencing Homelessness | 0.00% |
| Patients Who Are Residents of Public Housing | 0.00% |
| Patients with Limited English Proficiency | 7.69% |
| Children Under 18 Years of Age | 0.00% |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed courses of COVID-19 oral antiviral medication received through the HRSA Health Center COVID-19 Therapeutics Program as the denominator.
